FDA unveils guidance for Covid-19 trials
The FDA on Wednesday issued new final guidance to help sponsors assure the safety of trial participants, maintain compliance with good clinical practice (GCP) and minimize the risks to trial integrity during the Covid-19 pandemic.
The guidance comes as the National Institutes of Health last week initiated the first Covid-19 vaccine Phase 1 trial in Seattle. Sanofi and Regeneron Pharmaceuticals also announced on Monday they have started a Phase 2/3 trial at medical centers in New York evaluating the IL-6 targeted Kevzara (sarilumab) in patients hospitalized with severe Covid-19.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.